<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1101</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2018-17-3-50-54</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Expression rate of ALK tyrosine kinase and TAG-72 oncoprotein in primary skin melanoma</article-title><trans-title-group xml:lang="ru"><trans-title>Частота экспрессии тирозинкиназы гена ALK и онкобелка TAG-72 при первичной меланоме кожи</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Titov</surname><given-names>K. S.</given-names></name><name xml:lang="ru"><surname>Титов</surname><given-names>К. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>86 Shosse Entuziastov, Moscow 111123</italic></p></bio><bio xml:lang="ru"><p><italic>111123 Москва, ш. Энтузиастов, 86</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rotin</surname><given-names>D. L.</given-names></name><name xml:lang="ru"><surname>Ротин</surname><given-names>Д. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>7 Mamonovsky Pereulok, Moscow 123001</italic></p></bio><bio xml:lang="ru"><p><italic>123001 Москва, Мамоновский пер., 7</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9534-2729</contrib-id><name-alternatives><name xml:lang="en"><surname>Kazakov</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Казаков</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><bold>Алексей Михайлович Казаков </bold></p><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><email>hordavii@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Micheeva</surname><given-names>O. U.</given-names></name><name xml:lang="ru"><surname>Михеева</surname><given-names>О. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>86 Shosse Entuziastov, Moscow 111123</italic></p></bio><bio xml:lang="ru"><p><italic>111123 Москва, ш. Энтузиастов, 86</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Telezhnikova</surname><given-names>I. M.</given-names></name><name xml:lang="ru"><surname>Тележникова</surname><given-names>И. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>86 Shosse Entuziastov, Moscow 111123</italic></p></bio><bio xml:lang="ru"><p><italic>111123 Москва, ш. Энтузиастов, 86</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ryabchikov</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Рябчиков</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское ш., 24</italic></p></bio><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Moscow Clinical Scientific Center, Moscow Health Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Московский клинический научный центр ДЗМ»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">S.P. Botkin City Clinical Hospital, Moscow Health Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ «ГКБ им. С.П. Боткина ДЗМ»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-11-25" publication-format="electronic"><day>25</day><month>11</month><year>2018</year></pub-date><volume>17</volume><issue>3</issue><issue-title xml:lang="ru"/><fpage>50</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2018-11-25"><day>25</day><month>11</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-11-25"><day>25</day><month>11</month><year>2018</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1101">https://bioterapevt.abvpress.ru/jour/article/view/1101</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold>Determine the frequency of occurrence of tyrosine kinase expression of the mutated ALK and TAG-72 gene among patients with primary melanoma of the skin, to identify their association with a number of histological parameters, and to assess the diagnostic value of the determination of ALK and TAG-72.</p><p><bold>Materials and methods.</bold>Paraffin blocks with surgical material from 40 patients with primary skin melanoma. For routine histological examination, the material was fixed with 10 % neutral formalin for 24 h, poured into paraffin, sections were prepared with a thickness of 4–5 μm, stained with hematoxylin and eosin. IHC study with monoclonal antibodies D57.3 to ALK was performed on an immunostender – Ventana, with antibodies B72.3 to TAG-72 – on Thermo Fischer. As a detection system used: Envision – for TAG-72 and Ventana – for ALK.</p><p><bold>Results.</bold>ALK mutation was detected in 7 (12 %), TAG-72 – 4 (10 %) cases. Evaluation of the correlation force between the presence of ALK and TAG-72 showed a direct average coupling strength (correlation coefficient was 0.31). A direct correlation of the mean force between the presence of TAG-72 oncoprotein, ALK mutation and ulceration in the patient was found – the correlation coefficient was 0.53 and 0.68, respectively. There was a statistically significant association between the presence of ALK and lymphoid infiltration, which in most cases (57 %) was pronounced (p &lt;0.05).</p><p><bold>Conclusion.</bold>Comparing the positive sign of the expression of ALK – 17.5 % and TAG-72 – 10 %, and the positive of their simultaneous detection – 7.5 %, it can be concluded that further studies to determine their diagnostic value are promising. The presence of severe lymphoid infiltration in ALK-positive patients claims a diagnostic value in primary skin melanoma.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования </bold>– определить частоту экспрессии тирозинкиназы мутированного гена ALK и онкобелка TAG-72 у пациентов с первичной меланомой кожи, определить их связь с рядом гистологических параметров и оценить диагностическую ценность определения ALK и TAG-72.</p><p><bold>Материалы и методы. </bold>Для рутинного гистологического исследования материал фиксировали 10 %-ным нейтральным формалином в течение 24 ч, заливали в парафин, готовили срезы толщиной 4–5 мкм, окрашивали гематоксилином и эозином. Иммуногистохимическое исследование с моноклональными антителами D57.3 к ALK проводилось на иммуностейнере Ventana, с антителами B72.3 к TAG-72 на иммуностейнере Thermo Fischer.</p><p><bold>Результаты. </bold>ALK-мутация была обнаружена в 7 (12 %), TAG-72 – в 4 случаях из 40. Оценка корреляционной силы между экспрессией ALK и TAG-72 показала прямую среднюю силу связи (коэффициент корреляции составлял 0,31). Была выявлена прямая связь средней силы между наличием у пациента онкомаркера TAG-72, мутации ALK и изъязвлением – коэффициент корреляции составил 0,53 и 0,68 соответственно. Наблюдалась статистически значимая связь между наличием ALK и лимфоидной инфильтрацией, которая в большинстве случаев была выраженной (p &lt;0,05).</p><p><bold>Выводы. </bold>Сопоставляя позитив признака экспрессии ALK (17,5 %) и TAG-72 (10 %) и позитив их одновременного обнаружения (7,5 %), можно сделать вывод о том, что дальнейшие исследования по определению их диагностической ценности перспективны. Наличие выраженной лимфоидной инфильтрации у ALK-позитивных пациентов претендует на диагностическое значение при первичной меланоме кожи.</p></trans-abstract><kwd-group xml:lang="en"><kwd>melanoma</kwd><kwd>ALK</kwd><kwd>lymphoid infiltration</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>меланома</kwd><kwd>ALK</kwd><kwd>лимфоидная инфильтрация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Evans M.S., Madhunapantula S.V., Robertson G.P., Drabick J.J. Current and Future Trials of Targeted Therapies in Cutaneous Melanoma. Adv Exp Med Biol 2013;779:223–55. DOI:10.1007/978-1-4614-6176-0_10. PMID: 23288642.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Dhomen N., Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009;23(3):529–45. PMID: 19464601.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Jazirehi A.R., Lim A., Dinh T. PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Am J Cancer Res. 2016;6(10):2117–28.PMID: 27822406.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Titov K.S., Chikileva I.O., Kiselevskiy M.V., Kazakov A.M. Lymphoid infiltration, as a predictor of successful immunotherapy with melanoma. Malignant Tumors 2017;1:61–6. DOI:10.18027/2224-5057-2017-1-61-66.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Yeh I. Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. Department of Dermatology, Universityof California San Francisco, SanFrancisco, CA, USA.2016, Jun 28; 5. (F1000FacultyRev):1529. DOI:10.12688/f1000research.8247.1 PMID: 27408703.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Roskoski R.Jr. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res 2017;117:343–56. DOI:10.1016/j.phrs.2017.01.007. PMID: 28077299.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Montavon G., Jauquier N., Coulon A. et al. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget 2014;5:4452–66. PMID: 24947326.PMCID: PMC4147337.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Takezawa K., Okamoto I., Nishio K. et al. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011;17(8):2140–8. PMID: 21415216.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117–34. DOI:10.1016/j.cell.2010.06.011. PMID: 20602996.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Busam K.J., Villain R.E., Lum T. et al. Primary and metastatic cutaneous melanomas express ALK through alternative transcriptional initiation. Am J Surg Pathol. 2016;40(6):786–95. PMID: 26872010. PMCID: PMC5037961.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sosman J.A., Margolin K.A. Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. Curr Oncol Rep. 2009;11(5):405–11. PMID: 19679016.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Obenauf1 A.C., Zou Y., Ji A.L. et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015;520(7547): 368–72. DOI: https://doi.org/10.1038/nature14336.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Schulte J.H., Bachmann H.S., Brockmeyer B. et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining facto rof an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res 2011;17:5082–92. PMID: 21632861.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Cheng D.T., Mitchell T.N., Zehir A. et al. Memorial sloan ketter ingintegrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based nextgeneration sequencing clinical assay for solid tumor molecular oncology. J.Mol. Diagn 2015;17:251–64. PMID: 25801821.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Couts K.L., Bemis J., Turner J.A. et al. ALK Inhibitor response in melanomas expressing eml4-alk fusions and alternate ALK isoforms. Mol Cancer Ther. 2018;17(1):222–3. PMID: 29054983.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Deo Y.M., Tibor K. Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor. 1997. Pub. No.:WO/1999/019362 International Application No.: PCT/us 1997/018428.</mixed-citation></ref></ref-list></back></article>
